Journal of Cancer Research and Clinical Oncology

Journal: Journal of Cancer Research and Clinical Oncology

Abbreviation

J. Cancer Res. Clin. Oncol.

Publisher

Springer

ISSN

0171-5216
1432-1335

Show all metadata

Search Results

Publications 1 - 6 of 6

Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
Ristow, Oliver; Gerngross, Carlos; Schwaiger, Markus; et al. (2014)
Journal of Cancer Research and Clinical Oncology
Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder
Berndt, Alexander; Anger, Katharina; Richter, Petra; et al. (2006)
Journal of Cancer Research and Clinical Oncology
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model
Menssen, Hans D.; Harnack, Ulf; Erben, Ulrike; et al. (2018)
Journal of Cancer Research and Clinical Oncology
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient
Locher, Ricarda; Erba, Paola A.; Hirsch, Burkhard; et al. (2014)
Journal of Cancer Research and Clinical Oncology
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours
Spitaleri, Gianluca; Berardi, Rossana; Pierantoni, Chiara; et al. (2013)
Journal of Cancer Research and Clinical Oncology
Purpose L19-TNF is an armed antibody that selectively targets human TNF to extra domain B-fibronectin on tumour blood vessels. We performed a phase I/II first-in-man trial with L19-TNF monotherapy in metastatic solid cancer patients to study safety and signs of clinical activity. Methods Six cohorts of patients were treated with increasing (1.3–13 μg/kg) doses of intravenous L19-TNF on day 1, 3, and 5 of repeated 3-weekly cycles, and 12 colorectal cancer patients were treated at 13 μg/kg. PK, antibody formation, changes in lymphocyte subsets, 5-HIAA plasma levels as well as safety and clinical activity were analysed. Results Thirty-four patients received at least one L19-TNF dose. The serum half-life of L19-TNF at 13 μg/kg was 33.6 min, and maximum peak serum concentration was 73.14 μg/L. Mild chills, nausea and vomiting but no haemato- or unexpected toxicity were observed. Grade 3 lumbar pain in bone metastasis was the only dose-limiting toxicity found in one patient. Objective tumour responses were not detected. Transient stable disease occurred in 19 of 31 evaluable patients. Conclusions Intravenous L19-TNF on day 1, 3, and 5 of a 3-weekly schedule was safe up to 13 μg/kg, but did not result in objective tumour responses. The maximally tolerated dose (MTD) was not reached, allowing for further dose escalation of L19-TNF possibly in combination with chemotherapy.
B and C domain containing tenascin-C
Richter, Petra; Tost, Markus; Franz, Marcus; et al. (2009)
Journal of Cancer Research and Clinical Oncology

Publications 1 - 6 of 6

Journal: Journal of Cancer Research and Clinical Oncology

Abbreviation

Publisher

Journal Volumes

ISSN

Description

Filters

Search Results